Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Clinical trials sponsored by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd., explained in plain language.
A subsidiary focused on biological therapy development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take aim at Hard-to-Treat leukemia Results expected Dec 2026 (estimated)
- New cell therapy B019 takes on tough lymphoma in first human trial Results expected Dec 2026 (estimated)